Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ROIV is expected to report earnings to fall 207.04% to -29 cents per share on August 17
Q2'26
Est.
$-0.30
Q1'26
Beat
by $0.57
Q4'25
Missed
by $0.07
Q3'25
Beat
by $0.15
Q2'25
Missed
by $0.08
The last earnings report on May 20 showed earnings per share of 28 cents, beating the estimate of -28 cents. With 2.24M shares outstanding, the current market capitalization sits at 25.10B.